AstraZeneca's Fredrickson On Its Cancer Ambitions

Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.

Cancer cells on scientific background.3d illustration

AstraZeneca PLC has been on a roll of late. Better than expected third quarter financial results and strong showings at recent medical meetings came during a second half of briskly paced positive Phase III data read-outs and approvals.

Much of the positive news flow has come from its oncology portfolio (see Exhibit 1), one of the firm’s three...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo